Adapting For ADAPT: lighten the load with the MiniMed™ 780G’s advanced automation features

Wouldn’t it be great if there was a system that just took care of the nitty and gritty parts of your health for you? A system which could automate important routine tasks around managing your diabetes, so you can have more free time to do the things that matter most to you? How about a system that gives you an abundant amount of information about your glucose trends, so you can work together with your diabetes healthcare team to create a treatment plan based on your needs? Thanks to extensive research and development of innovative technology like the MiniMed 780G^TM system, it seems that people living with type 1 diabetes can begin to worry less about their glucose levels and spend more time enjoying life.

The ADAPT study¹

Recently, a multi-country study known as ADAPT investigated the potential of the MiniMed^TM 780G system in comparison to multiple daily injections (MDI) plus intermittently scanned CGM. 82 people across France, Germany, and the UK living with type 1 diabetes were split into two equal groups. One group continued on MDI plus intermittent CGM, while the other group used the MiniMed 780G^TM system. After 6 months, investigators analysed the results. Compared to those using MDI, those on the MiniMed^TM 780G found a greater improvement to both their HbA1c as well as their TIR. One of the ways the MiniMed^TM 780G insulin pump achieved this was through its advanced automation features.

How the MiniMed^TM 780G can lighten the load

A major finding from further analysis² was that the more time spent using the automation features of the pump, driven by an advanced algorithm known as SmartGuard^TM, the better the user’s TIR. This result highlighted the advantage of the pump’s advanced automation features and the SmartGuard^TM algorithm driving force behind it.

The SmartGuard^TM algorithm is capable of automatically delivering both basal and correction insulin doses. It can do this as frequently as every 5 minutes as needed, based on the input from your continuous glucose monitor (CGM). Unlike MDI, which uses readings at a set moment, the SmartGuard^TM can react to your glucose in real-time. By automatically topping up or withholding small corrective doses through monitoring your glucose trends, highs and lows can be prevented before they even happen. This means those living with type 1 diabetes can get on with living, minus that constant worrying about what your glucose levels are up to.

Keeping connected

Having access to all this valuable information provided by system through your CareLink™ Personal software is a game-changer for those living with type 1 diabetes. The abundance of data processed has the potential to tell you a little more about yourself, such as what factors (certain foods, exercise routines, maybe even some emotions) may increase or decrease your glucose levels. This self-awareness is a crucial ingredient to empowering yourself no matter what stage you are at on your diabetes journey.

Being able to access the information about your diabetes management is invaluable for your diabetes healthcare team. It allows them to finetune your treatment plan accordingly and react more quickly to any necessary changes. As a case in point, a survey of diabetes healthcare teams across Germany, France, Spain, Italy, the UK, and Nordics found the vast majority were happy with the MiniMed^TM 780G’s clinical outcomes and its ease of use.³

Lighten the load on the go

The MiniMed^TM 780G system also wirelessly connects to the MiniMed^TM Mobile app enabling you to track and easily view glucose levels and trends directly from your phone. This means you don’t need to keep digging out your pump to check it. There are options to customise alerts based on your needs, as well as having helpful reminders in the form of alarms.

Final thoughts

In recognition of how much brain power living with type 1 diabetes can consume, there are a multitude of tools available to help lighten the load. The MiniMed^TM 780G system is one of them. With the SmartGuard^TM algorithm taking care of your highs and lows, you can apply your brain space to something other than constantly watching your insulin dosages. By leveraging diabetes technology and your diabetes healthcare team to their full potential, you can tailor your treatment and optimise your glucose management. It’s a win-win.

References

1. Choudhary P, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diab Endocrinol. 2022.
2. Castañeda, J, et al. Predictors of time in target glucose range in real-world users of the MiniMed 780G system. Diabetes Obes Metab. 2022; 1- 10.
3. Seagrove 2021: N = 270 - Data based on Prescription filled by HCP in Germany, France, UK, Italy, Spain and Nordics and Benelux.

* Information contained herein is not medical advice and should not be used as an alternative to speaking with your diabetes healthcare team. Discuss indications, contraindications, warnings, precautions, potential adverse events, and any further information with your diabetes healthcare team.